



## Grants Awarded through Expression of Interest Process 1 December 2023 to 30 September 2024

ANTIVIRAL STRATEGIES	
<b>Dr Hao Song</b>	Nanotechnology enabled long-acting antiretroviral therapy for improved HIV treatment adherence
<b>Prof Gilda Tachedjian</b>	Novel gel to promote vaginal colonisation of live biotherapeutics for HIV prevention
<b>Dr Marcel Doerflinger</b>	Combination antiviral and pro-apoptotic strategies to eliminate HTLV1c infection in vivo
DIAGNOSTICS/PROGNOSTICS	
<b>A/Prof Thomas Tu</b>	Cyclic peptide-based assays to increase access to hepatitis B diagnosis and testing
<b>A/Prof Xiaonan Zhang</b>	The effects of fatty liver disease on the diagnostic performance of Capsid-Antibody-Complexes (CACs) on chronic hepatitis B
<b>Dr Jun Zhang</b>	Enhancing the Detection of Human T-Lymphotropic Virus Type 1 (HTLV-1) with State-of-the-Art Microfluidics
VACCINES/PREVENTION AND IMMUNOTHERAPY	
<b>Prof Tony Cunningham</b>	Further development of the interferon-CAR T cell strategy for reducing latent HIV infection
<b>Dr Behnaz Heydarchi</b>	Unmasking HIV-1 neutralisation mechanism of an ultra-potent HIV neutralising monoclonal antibody
<b>Prof Hans Netter</b>	Antigenic and immunogenic characterisation of subviral particles (SVPs) derived from the HBV/C4 strain prevalent in Aboriginal Australians
<b>Dr Belinda de Villiers</b>	Magnetized Nano-Glycan-Traps to Dampen HIV Transmission